Encouraging preliminary Phase I/II data in first of kind oncology study
Today 4D Pharma has released encouraging preliminary safety and clinical observation data from its Phase I/II study of MRx0518 in combination with Keytruda® in patients with advanced and progressive malignancies. Initial data shows the therapy combination was well-tolerated producing no drug-related serious adverse events, and that early clinical observations show that two patients demonstrated a partial response and a third patient presented stable disease - a significant feature given the advanced stage of the disease. Efficacy data is clearly preliminary, in a small patient cohort, and the sustainability of the response unproven; however, to our knowledge, this is the first of its kind clinical data to be reported on any LBP product from an oncology study. This highlights the significant scientific advancements the Group is making as a first-mover in the oncology field, and collectively the announcement raises credibility of using the LBP therapy approach in oncology. We continue to believe that a comprehensive data package on MRx0518 across multiple oncology indications is highly attractive offering opportunities for value creation.
06 Nov 19
MSD platform collaboration: a good strategic fit
4D pharma this morning has announced a research collaboration and option to license agreement with Merck & Co (MSD) potentially worth up to $1bn to discover and develop live biotherapeutics (LBPs) for vaccines. This represents a substantial milestone for the Group, adding concrete endorsement for the MicroRx® platform from a leading industry partner, and illustrates the platform’s ability to create nearand long-term value.
08 Oct 19
Small Cap Feast
Kaspi.kz, the largest Paym ents, Marketplace and Fintech Ecosystem in Kazakhstan w ith a leading m arket share in each of its key products and services, has postponed its Initial Public Offering due to unfavourable market conditions. Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019. Pricing rumoured at 115p to 145p implying valuation of up to $1.8bn
DDDD CCS IKA SGM SPA PPH SOLO SO4 RQIH QFI
08 Oct 19
Interims sets out near-term data catalysts
Today’s interims highlight the solid clinical development made during the year, and we expect value-crating interim data readouts from both lead candidates, Blautix and MRx0518, within the next six calendar months. We continue to believe 4D Pharma is set apart as a developer of live biotherapeutics and we reiterate our positive stance on 4D Pharma.
30 Sep 19
Small Cap Feast
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019. VAALCO Energy, Inc. (NYSE: EGY), an independent energy com pany focused on developm ent and production assets in West Africa, today announces its formal intention to seek a Standard Listing on the Main Market of London Stock Exchange ("LSE"), to complement its existing Listing on the New York Stock Exchange. Kaspi.kz, the largest Paym ents, Marketplace and Fintech Ecosystem in Kazakhstan w ith a leading m arket share in each of its key products and services, announces today the expected publication of a registration document that has been submitted for approval to the FCA and its potential intention, subject to market conditions, to undertake an initial public offering. Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019.
DDDD NAK GFIN CCS PHD MED OSI MWE THRU
23 Sep 19
An early-adopter in the growing microbiome field
4D pharma plc is a drug developer of live biotherapeutic products (LBPs), using individual bacteria strains to target certain diseases. The microbiome is a growing and exciting field of drug development and medicine, and 4D pharma is wellpositioned as an early adopter to become a market leader with its diverse portfolio of potentially disruptive LBPs. We believe there are multiple opportunities for value creation and potential upside, and that pending proof-of-concept data and business development would add significant endorsement to the Group’s investment case.
14 Aug 19
Small Cap Feast
Interswitch, a Nigeria-based payments firm, has hired advisers to resurrect plans for a stock-market listing in London and Lagos later this year, which may value the financial technology company at $1.3 billion to $1.5 billion. Voyager AIR The Company will focus on the acquisition, leasing and management of primarily widebody aircraft, with asset management services to be provided by Amedeo Limited the IPO will comprise a Placing and Offer for Subscription of Shares to raise up to approximately US$200m. Roxi Music UK music streaming service plans London IPO as it goes up against Spotify. They have appointed investment bank Arden Partners for an initial public offering (IPO) on the London Stock Exchange later this year.
DDDD SIM THAL SML FIPP MED GGP TOM SBIZ
25 Jul 19
Small Cap Feast
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019. Alumasc Group plc, the prem ium building products, system s and solutions group, has announced its intention to m ove from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019
DDDD SAR TAM ESRE TPG ARB BEM ANGS EOG
03 Jun 19
Small Cap Feast
Essensys plc—a provider of mission-critical SaaS platforms and on-demand cloud services to the high growth flexible workspace industry, plans to join AIM. Offer TBC, expected 29 May 2019. Induction Healthcare Group plc—a healthcare technology company focused on streamlining the delivery of care by Healthcare Professionals looking to join AIM. Expected raise of £14.58m at 115p, market cap of £34.07m. Expected 22 May 2019. SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019. Alumasc Group plc, the premium building products, systems and solutions group, has announced its intention to move from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019
DDDD SAR MYSL SEE BLV LID IND ERGO AEO
16 May 19
Small Cap Breakfast
Sensyne Investments - healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care. Raising £60m. Mkt Cap £225m. Due 17 Aug. Path Investments (PATH) -RTO of a 50 per cent. participating interest in the producing Alfeld-Elze II gas field located 22 kilometres south of Hannover in Germany. Offer TBA. Due late Aug. Vitesse Media (VIS) — To be renamed Bonhill Group. RTO of the trade and assets of InvestmentNews, a Business Information and Data & Insight brand supporting the US financial adviser and wealth manager community Due 17 Aug. Raising £18.6m at 80p. Mkt cap £26.7m. Kropz PLC-Intention to float by the emerging plant nutrient producer with an advanced stage phosphate mining project in South Africa and exploration assets in West Africa
DDDD PHSC REAT SUMO GLR FLX KRS MTFB MOS CAL
14 Aug 18
Small Cap Breakfast
Anexo -specialist integrated credit hire and legal services group. Offer TBA. Due 19 June. i-nexus—develops and provides strategy execution software to assist global enterprises in effective execution of their strategic plans and initiatives looking to jon AIM. Offer TBC, expected 19 June Yellow Cake will use its expertise to generate value through the ownership of physical U3O8 (Uranium) together with a range of activities and opportunities connected with owning physical U3O8. Acquiring supply contract for up to $170m. Offer TBA. Tekmar— technology provider of protection systems for subsea cable, umbilical and flexible pipes and offshore engineering services—Offshore wind farms and Oil & Gas. Revenue of £21.9m and Adjusted EBITDA of £4.9m Offer TBA Knights Group— UK regional legal and professional services businesses. FYApr18 rev £34.9 million and adjusted operating profit was £6.8 million excluding Turner Parkinson (acquiring on IPO). Offer TBA Aquis Exchange—a founder-led, pan-European Multilateral Trading Facility and exchange and regulatory technology developer and service provider is looking to join AIM. Offer TBC, expected 20 June. TransGlobe Energy Corporation—an independent international upstream oil and gas company with headquarters in Calgary, Canada is looking to join AIM. No Capital to be raised, market cap of £131m. Expected 29 June Block Energy— UK based oil exploration and production company whose main country of operation is the Republic of Georgia. Raising £5m at 4p. Mkt cap £10.3m. Due 11 June. Strongbow Exploration (TSX:SBW) intends to dual list on AIM. Holds rights to the South Crofty underground tin mine, a former producing tin mine located in the towns of Pool and Camborne, Cornwall . The project is estimated to require the Company to raise £25 million over the next 18 months to progress to a production decision. Offer TBS. Due June. Yew Grove REIT—newly formed Company will pursue its investment objective by investing in a diversified portfolio of Irish commercial property. Raising €75m at €1. Due 8 June
DDDD JOUL ZIN IHC KWG ARTA WCH TSL ATMA
07 Jun 18
Small Cap Breakfast
Team17 Group -video games label and creative partner for independent developers. Since 2014, delivered a revenue CAGR of 69% (31 December 2015 to 31 December 2017), with revenues of £29.6m and Adjusted EBITDA of £12.9m. Offer TBA Urban Exposure, a newly formed company which been established to pursue two main strategies in the residential development finance market - asset management of development finance loans and direct lending into development finance loans, looking to join AIM. Offer raising £150m at £1, market cap of £165m, expected 9 May 2018 Supreme, POSTPONED a leading manufacturer and supplier of branded consumer batteries, a manufacturer and supplier of branded and licensed consumer lighting and a leading manufacturer and supplier of vaping products in the United Kingdom, is looking to join AIM. Offer TBC, expected May 2018 Serinus Energy -international upstream oil and gas exploration and production company. Its principal assets are located in Romania (development phase) and Tunisia (production phase). Raising c.£10m. Offer TBA. Due mid May.
DDDD ARIX AVO ODX DUKE OPTI IDEA TRT EME FARN
08 May 18
Small Cap Breakfast
Kore Potash— advanced stage mineral exploration and development company whose primary asset is its interest in the Sintoukola Project, a potash project located in the Republic of Congo. ) Measured, Indicated and Inferred Mineral Resource of 5,953Mt at an average grade of 22.0% KCl. Offer TBA. Due end March. Perfomatrix PLC, a global end to end Performance Marketing technology and services company headquartered in the UK, is looking to join AIM in early April 2018, offer TBC Crusader Resources, an ASX-listed public company incorporated in Australia, which is primarily focused on the exploration and development of gold assets in Brazil. Offer TBC, expected late March. SimplyBiz, a Financial Services Firm, looking to join AIM raising £30m via placing and £34.6m via a sale of existing ordinary shares at 170p giving a market cap of £130m. Expected 4 April Bacanora Lithium—Readmission. No new money. Mkt cap £140m. Due 21 March. the new holding company for Bacanora Minerals Ltd Core Industrial REIT—established to invest in Irish-based industrial properties, predominantly located in the Greater Dublin Area. Vendor placing and new funds to a total of €225m, Target gross proceeds €207m. Expected Mid March Polarean - Medical drug-device combination company operating in the high resolution medical imaging market. Offer TBC. Due 26 March
DDDD IDHC AHCG WJG MED MSYS BKS DCTA BBSN SDX
21 Mar 18
2016 Financial Results
4D Pharma (LSE: DDDD) is pioneering the development of Live Biotherapeutic Products (LBPs) as medicines based on the function of the microbiome in health and disease. This morning 4D reported its results for 2016, a year in which both the technology and pipeline of the company progressed significantly. 4D generated positive phase I clinical results for Blautix in irritable bowel syndrome (IBS) and entered clinical trials in paediatric Crohn’s disease (pCD) with Thetanix. In addition, 4D further developed its operations in the field of diagnostics and manufacturing through strategic acquisitions in Cork (Ireland) and León (Spain), respectively. Despite these acquisitions and increased investments in R&D (£10.2m), 4D ended the year with cash and equivalents of £68.8m. We believe that with its scientific leadership in the field of microbiome research and LBP development, 4D provides an excellent opportunity for investors to gain exposure to this innovative new class of medicines.
27 Apr 17
The new age of live-biotherapeutics
The awareness of the microbiome and its relationship to human health and disease has grown in recent years and now attracts much interest from the global pharmaceutical and biotechnology industry. The human microbiome is comprised of over 100 trillion microbes which live in a number of different niches on or in the body, but mostly in the gut. The realisation that these microbes are more than mere ‘passengers’ has come about as alterations in the numeric and functional diversity of the microbial community have been characterised in far greater detail than ever before. Driven by technology innovations the growing depth of microbiome knowledge has enabled the dissection of associations between specific microbial communities and certain disease states. In this context, the potential to exploit the microbiome to treat or prevent the development of diseases is now being more fully explored by scientists and clinicians in both academia and industry. Strategies to therapeutically exploit the gut microbiome include standard small-molecule drug approaches, selective dietary supplements and bacteria themselves as therapeutic agents, so called live biotherapeutic products.
DDDD ASMB MCRB
07 Mar 17
Small Cap Breakfast
AFC Energy (AFC.L) | Touchstone Innovations (IVO.L) | 4D Pharma (DDDD.L) | FairFX (FFX.L) | Versarien (VRS.L) | Abzena (ABZA.L) | MetalNRG (NEX:MNRG) | Valiant Investments ( N E X : V A L P ) | Vernalis (VER.L) | Satellite Solutions (SAT.L)
DDDD AFC IVO EQLS VRS ABZA VER SAT
06 Mar 17
Small Cap Breakfast
Ultimate Products—The Telegraph reports Jim McCarthy, former chief of Poundland has been appointed Chairman of Ultimate Products ahead of a £100m listing in H1 2017. Ultimate Products owns the Beldray cleaning brand and the licence to sell Russell Hobbs and Salter electrical products in the UK. ECSC—Schedule 1 from provider of cyber security services. Raising £5m. Vendor sale £0.9m. Target date 14 Dec. Expected market cap £15m, with issue price of 167p. RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m
DDDD MPM TYM EMH UTW VLS MSYS SEE bmn BIDS
13 Dec 16
FastForward Innovations (FFWD.L) | Elegant Hotels (EHG.L) | Nektan (NKTN.L) | Scancell Holdings (SCLP.L) | 4D Pharma (DDDD.L) | Safeland (SAF.L) | Palace Capital (PCA.L) | Image Scan Holdings (IGE.L) | MBL Group (MUBL.L) | 365Agile Group (365.L)
DDDD FFWD EHG NKTN SCLP SAF PCA 365 MUBL IGE
22 Aug 16
US pharma deals but don’t forget the rest!
While Abbvie and Pharmacyclics work out their $21bn nuptial party arrangements, there has also been some positive news over here on the UK biotech scene. British biotech company Heptares, has been bought by Japan’s Sosei in a deal worth around £250m. Which if you had not just read the $21bn number would seem like a result. This for just two COPD products, but then it has been ‘just’ hard slog since the 1990s to get to this place. Astra Zeneca signed a three year deal with Orca Pharmaceuticals for its Auto-immune program to the tune of $122m which has taken considerably less time, and overall there are definitely signs of life across the sector. So much so that Messrs Woodford and Mellon have also announced plans to invest in a significant way.
DDDD TAIH ABA TILS ODX PYC CTI EDEN DEMG VRP
09 Mar 15
Venture life helps the Chinese Aged, SQS gets on the Italian Job, what next for Next 15
DDDD placing, ABC acquisition, ABDP new contract win, BMK preliminary results, CYAN £1m order, EKF collaboration, EMIS contract award, FPM new exploration licences, FITB joins Jawbone, partners with Cancer Research UK and court case judgement, GFM production update, HAYT £3m secured loan note programme and contract win, LWRF preliminary results, NFC proposed placing and trading update, SQS acquisition, STAF full year results, VLG distribution deal .
DDDD ABC ABDP BMK EKF EMIS FPM GFM HAYT LWRF NFC SQS STAF VLG CYAN BIDS
03 Feb 15